Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of PH3 in Diabetic Nephropathy
Sponsor: PhytoHealth Corporation
Summary
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy. The secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2010-08
Completion Date
2015-09
Last Updated
2026-09-18
Healthy Volunteers
No
Conditions
Interventions
PH3
Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
Locations (3)
Taichung Veterans General Hospital
Taichung, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan